Supernus Pharmaceuticals (NASDAQ:SUPN) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report report published on Monday, MarketBeat.com reports. The firm issued an overweight rating and a $57.00 target price on the specialty pharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $38.06 on Monday. The firm’s fifty day moving average is $36.34 and its two-hundred day moving average is $33.15. Supernus Pharmaceuticals has a 52-week low of $25.53 and a 52-week high of $39.37. The company has a market cap of $2.10 billion, a P/E ratio of 35.57 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The company had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. During the same period in the previous year, the business earned ($0.29) earnings per share. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. As a group, analysts forecast that Supernus Pharmaceuticals will post 2.37 EPS for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now owns 13,315 shares in the company, valued at $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now directly owns 8,200 shares of the company’s stock, valued at $303,236. This represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 over the last 90 days. Company insiders own 9.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC grew its position in shares of Supernus Pharmaceuticals by 47.6% during the 2nd quarter. Armistice Capital LLC now owns 5,272,000 shares of the specialty pharmaceutical company’s stock worth $141,026,000 after buying an additional 1,700,000 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Supernus Pharmaceuticals by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company’s stock worth $76,690,000 after buying an additional 309,966 shares during the last quarter. Stephens Investment Management Group LLC increased its position in Supernus Pharmaceuticals by 1.8% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares in the last quarter. Pacer Advisors Inc. raised its stake in Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after buying an additional 403,028 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Supernus Pharmaceuticals by 26.4% in the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock worth $45,077,000 after acquiring an additional 351,900 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.